公开(公告)号：US20230192896A1

公开(公告)日：2023-06-22

申请号：US16462878

申请日：2017-11-22

Applicant: Bioverativ Therapeutics Inc.

Inventor： Robert T. PETERS ,  Nina LEKSA ,  Bradley R. PEARSE ,  John KULMAN ,  Maria ALEMAN ,  Allison GOODMAN

IPC: C07K16/46 ,  A61P7/04

CPC classification number: C07K16/468 ,  A61P7/04 ,  C07K2317/565 ,  C07K2317/31 ,  C07K2317/34

Abstract: The present disclosure provides antibodies that selectively binds to specific forms of clotting factors, in particular, antibodies that specifically binds to activated factor IX (FIXa) wherein the anti-FIXa antibody or an antigen binding portion thereof preferentially binds to FIXa in the presence of FIXa and factor IX zymogen (FIXz), and antibodies that specifically bind to factor X zymogen (FXz) wherein the anti-FXz antibody or antigen binding portion thereof preferentially binds to FXz in the presence of FXz and activated factor X (FXa). Also provided are bispecific molecules (e.g., antibodies) comprising, e.g., an anti-FIXa antibody or antigen binding portion thereof and/or an anti-FXz antibody or antigen binding portion thereof. The disclosure also provides compositions encoding the disclosed antibodies and bispecific molecules, vectors, cells, pharmaceutical and diagnostic compositions, kits, methods of manufacture, methods of use, and immunoconjugates.